Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

ATNM

Actinium Pharmaceuticals Inc

Jun 21 • 04:00PM ET

7.31

Dollar change -0.24
Percentage change -3.18	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.72	Insider Own	3.62%	Shs Outstand	29.78M	Perf Week	-8.85%
Market Cap	217.69M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	28.71M	Perf Month	-17.49%
Income	-46.45M	PEG	-	EPS next Q	-0.41	Inst Own	25.39%	Short Float	6.30%	Perf Quarter	-19.76%
Sales	0.08M	P/S	2721.15	EPS this Y	17.21%	Inst Trans	6.71%	Short Ratio	5.16	Perf Half Y	51.03%
Book/sh	1.49	P/B	4.90	EPS next Y	69.42%	ROA	-48.80%	Short Interest	1.81M	Perf Year	-12.35%
Cash/sh	2.82	P/C	2.59	EPS next 5Y	-	ROE	-91.92%	52W Range	4.00 - 10.24	Perf YTD	43.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.80%	ROI	-102.57%	52W High	-28.61%	Beta	0.20
Dividend TTM	-	Quick Ratio	10.59	Sales past 5Y	-22.00%	Gross Margin	-917.28%	52W Low	82.75%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	10.59	EPS Y/Y TTM	-10.98%	Oper. Margin	-61645.68%	RSI (14)	35.03	Volatility	4.57% 4.82%
Employees	49	Debt/Eq	0.05	Sales Y/Y TTM	-10.00%	Profit Margin	-57346.91%	Recom	1.00	Target Price	28.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	27.61%	Payout	-	Rel Volume	1.19	Prev Close	7.55
Sales Surprise	-	EPS Surprise	17.99%	Sales Q/Q	-	Earnings	May 13	Avg Volume	351.08K	Price	7.31
SMA20	-9.69%	SMA50	-11.24%	SMA200	11.30%	Trades		Volume	418,552	Change	-3.18%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Initiated	Stephens	Overweight	$25
Sep-06-23	Initiated	HSBC Securities	Buy	$11.60
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight	$20
Aug-25-22	Initiated	B. Riley Securities	Buy	$16
Nov-05-20	Initiated	Alliance Global Partners	Buy	$25
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy	$2.75
Oct-23-17	Resumed	ROTH Capital	Buy	$6
Sep-14-17	Initiated	Maxim Group	Buy	$3
Aug-25-16	Initiated	ROTH Capital	Buy	$5
Feb-29-16	Initiated	H.C. Wainwright	Buy	$8
Oct-15-15	Initiated	FBR Capital	Outperform	$12
Oct-01-14	Initiated	MLV & Co	Buy	$16
Jul-22-14	Initiated	Canaccord Genuity	Buy	$16

Show Previous Ratings

Jun-20-24 09:40AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-18-24 08:45AM	Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions (Newsfile)
Jun-17-24 08:45AM	Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) (Newsfile)
08:00AM	Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress (PR Newswire)
Jun-14-24 08:30AM	Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial (PR Newswire)
08:30AM	Loading…
Jun-11-24 08:30AM	Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
08:30AM	Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
May-15-24 08:30AM	Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity (PR Newswire)
May-14-24 06:38PM	Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial (PR Newswire) +11.63%
10:24AM	3 Cheap Biotech Stocks to Buy Now: May 2024 (InvestorPlace)
07:46AM	Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target (MT Newswires)
May-13-24 08:30AM	Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
May-07-24 08:00AM	Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern (PR Newswire)
08:00AM	Loading…
Apr-18-24 08:00AM	Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting (PR Newswire) -8.00%
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -6.22%
Apr-01-24 08:00AM	Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting (PR Newswire) +9.32%
Mar-26-24 07:18AM	Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy (PR Newswire) -6.34%
Mar-15-24 06:15AM	High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment (InvestorPlace) +7.66%
Mar-11-24 07:30AM	Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand (PR Newswire) -9.54%
Feb-26-24 07:30AM	Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (PR Newswire) +21.14%
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-23-24 07:30AM	Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (PR Newswire)
Jan-02-24 07:30AM	Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (PR Newswire)
Dec-11-23 08:15AM	Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation (PR Newswire) -7.52%
07:45AM	Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
Dec-08-23 08:00AM	Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition (PR Newswire)
Nov-06-23 07:30AM	Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations (PR Newswire)
Nov-02-23 04:15PM	Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023 (PR Newswire) -15.50%
09:05AM	Loading…
09:05AM	Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial (PR Newswire)
Oct-31-23 08:15AM	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates (Zacks)
Oct-04-23 07:30AM	Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy (PR Newswire)
Sep-27-23 09:05AM	Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting (PR Newswire)
Sep-07-23 08:40AM	Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO (PR Newswire)
Aug-31-23 07:00AM	Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting (PR Newswire)
Aug-21-23 07:00AM	Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress (PR Newswire)
Aug-15-23 09:41AM	Actinium: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-23 07:00AM	Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit (PR Newswire)
Jun-26-23 07:00AM	SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data (PR Newswire)
Jun-23-23 08:00AM	Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting (PR Newswire) -6.94%
Jun-16-23 07:00AM	Actinium Pharma to Present at the Maxim Healthcare Virtual Conference (PR Newswire)
Jun-14-23 07:00AM	Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit (PR Newswire)
Jun-12-23 07:00AM	Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress (PR Newswire)
Jun-07-23 07:00AM	Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes (PR Newswire) +5.45%
May-22-23 07:00AM	Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers (PR Newswire)
May-17-23 06:34AM	Actinium: Q1 Earnings Snapshot (AP Finance)
May-11-23 11:18AM	Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA) (PR Newswire)
May-10-23 07:00AM	Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day (PR Newswire)
Apr-28-23 08:00AM	Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress (PR Newswire)
Apr-27-23 10:36AM	Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting (PR Newswire)
Apr-19-23 08:45AM	Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting (PR Newswire)
08:30AM	Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting (PR Newswire)
Apr-03-23 07:00AM	Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones (PR Newswire)
Mar-16-23 08:45AM	Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting (PR Newswire)
Mar-15-23 08:00AM	Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference (PR Newswire)
Feb-27-23 08:00AM	Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar (PR Newswire) +6.70%
Feb-24-23 04:04PM	Actinium Pharma Cratered 37% Over Two Days Here's Why, According To CEO Sandesh Seth (Investor's Business Daily)
Feb-18-23 04:30PM	Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
Feb-14-23 07:30AM	Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023 (PR Newswire)
Feb-06-23 07:30AM	Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies (PR Newswire)
Jan-17-23 07:30AM	Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference (PR Newswire) +7.29%
Jan-12-23 08:00AM	Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings (PR Newswire)
Dec-12-22 08:00AM	Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH (PR Newswire)
Dec-08-22 07:30AM	Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative (PR Newswire)
Nov-10-22 08:15AM	Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +5.72%
Nov-03-22 09:20AM	Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial (PR Newswire) -11.45%
Nov-02-22 08:17AM	Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization (PR Newswire) +8.75%
Oct-31-22 12:12PM	Actinium's stock jumps 22% on new data for its acute myeloid leukemia therapy (MarketWatch) +39.16%
12:00PM	Actinium Shares Are Trading Higher After Positive Data From Acute Myeloid Leukemia Trial (Benzinga)
06:00AM	Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
Oct-27-22 07:30AM	Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A (PR Newswire)
Oct-26-22 09:17AM	Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar? (Zacks) +9.72%
07:30AM	Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference (PR Newswire)
Oct-25-22 07:30AM	Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B (PR Newswire) +8.64%
Sep-26-22 07:30AM	Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference (PR Newswire)
Sep-21-22 07:30AM	Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones (PR Newswire)
Sep-08-22 01:50PM	With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium (Benzinga) +8.92%
07:00AM	Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-15-22 10:15AM	CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-11-22 08:55AM	Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-09-22 06:25PM	Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-04-22 07:35AM	Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.22%
May-19-22 09:40AM	Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-25-22 07:30AM	Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR (PR Newswire)
Apr-19-22 07:30AM	Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR (PR Newswire) +6.50%
Apr-13-22 03:36PM	Actinium (ATNM) Up on Commercialization Deal With Immedica (Zacks) +6.25%
Apr-12-22 07:00AM	Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa (PR Newswire) +24.01%
Apr-11-22 07:37AM	Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR (PR Newswire)
07:17AM	Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect (PR Newswire)
Feb-22-22 08:00AM	Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors (PR Newswire)
Jan-05-22 07:30AM	Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRP Immunotherapy (PR Newswire) -7.45%
Dec-14-21 08:00AM	Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML (PR Newswire) -7.13%
07:45AM	Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting (PR Newswire)
Dec-13-21 07:30AM	Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting (PR Newswire)
Dec-08-21 08:25AM	Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit (PR Newswire)
Nov-12-21 08:15AM	Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference (PR Newswire)
08:00AM	Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference (PR Newswire)
Nov-04-21 09:05AM	Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy (PR Newswire)
09:03AM	Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting (PR Newswire)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATNM

Actinium Pharmaceuticals Inc

Upgrade your FINVIZ experience